Jason A Keyes
CIK 1678152 · Chief Financial Officer · last filed 2026-05-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$355.8K
Companies
4
Total Filings
42
Lifetime Open-Market Net
-$384.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACTU | Director | — | $2.02 | — | $0 | 3 | 2026-05-22 |
| EQ | Chief Financial Officer | 126,633 | $2.81 | $355.8K | -$384.0K | 30 | 2025-02-19 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | 40,000 | $12.58 | $503.0K | $0 | 4 | 2022-06-24 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | EVP, Chief Financial Officer | 3,031 | — | — | $0 | 5 | 2017-10-17 |
Recent Filings · Page 5 of 5
42 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-12-02 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | +291 | $486 | EDGAR |
| 2016-07-14 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 41–42 of 42
Prev
Page 5 of 5
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.